Orexo AB (publ) (ORXOY) Research

Orexo AB (publ), a specialized pharmaceutical firm established in 1994 and based in Uppsala, Sweden, focuses on creating and marketing both drug-based treatments and digital therapeutic solutions. Its operations span the United States, Europe, and the United Kingdom. The company's commercialized offerings include Zubsolv, prescribed for opioid dependence; Abstral, which addresses breakthrough pain in cancer patients; and Edluar, utilized for managing brief periods of insomnia. Orexo's development pipeline encompasses several pharmaceutical candidates: OX124 for naloxone rescue, OX125 for nalmefene rescue, OX640 designed for allergic reactions, and OX338, a sublingual ketorolac tablet intended for moderate to severe pain relief. Additionally, Orexo is advancing the OX-MPI program, which targets microvascular diseases associated with chronic inflammatory conditions. In the realm of digital health, Orexo provides deprexis for treating mild to severe depression, vorvida for individuals with alcohol use disorder, and modia for opioid use disorder.

Open Orexo AB (publ) (ORXOY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.